Back to Search Start Over

Elevated Src family kinase activity stabilizes E-cadherin-based junctions and collective movement of head and neck squamous cell carcinomas.

Authors :
Veracini L
Grall D
Schaub S
Beghelli-de la Forest Divonne S
Etienne-Grimaldi MC
Milano G
Bozec A
Babin E
Sudaka A
Thariat J
Van Obberghen-Schilling E
Source :
Oncotarget [Oncotarget] 2015 Apr 10; Vol. 6 (10), pp. 7570-83.
Publication Year :
2015

Abstract

EGF receptor (EGFR) overexpression is thought to drive head and neck carcinogenesis however clinical responses to EGFR-targeting agents have been modest and alternate targets are actively sought to improve results. Src family kinases (SFKs), reported to act downstream of EGFR are among the alternative targets for which increased expression or activity in epithelial tumors is commonly associated to the dissolution of E-cadherin-based junctions and acquisition of a mesenchymal-like phenotype. Robust expression of total and activated Src was observed in advanced stage head and neck tumors (N=60) and in head and neck squamous cell carcinoma lines. In cultured cancer cells Src co-localized with E-cadherin in cell-cell junctions and its phosphorylation on Y419 was both constitutive and independent of EGFR activation. Selective inhibition of SFKs with SU6656 delocalized E-cadherin and disrupted cellular junctions without affecting E-cadherin expression and this effect was phenocopied by knockdown of Src or Yes. These findings reveal an EGFR-independent role for SFKs in the maintenance of intercellular junctions, which likely contributes to the cohesive invasion E-cadherin-positive cells in advanced tumors. Further, they highlight the need for a deeper comprehension of molecular pathways that drive collective cell invasion, in absence of mesenchymal transition, in order to combat tumor spread.

Details

Language :
English
ISSN :
1949-2553
Volume :
6
Issue :
10
Database :
MEDLINE
Journal :
Oncotarget
Publication Type :
Academic Journal
Accession number :
25779657
Full Text :
https://doi.org/10.18632/oncotarget.3071